Stock Taper
SCREENER COMPARE ANY 2 STOCKS
IMCR
IMMUNOCORE HOLDINGS PLC
NASDAQ
$36.62
▼ DOWN 0.35% (-0.13)

KEY STATISTICS

Market Cap$1.86 B
52w High$40.72
52w Low$27.55
Dividend Yield—
Frequency—
P/E-103.32
Volume300.32K
Shares Out.50.83M

COMPANY

LEADERSHIP

Bahija Jallal
CHIEF EXECUTIVE
Bahija Jallal

COMPENSATION 2026

Salary$765,000
Stock Awards$2,819,992
Incentive Plan Pay$688,500
All Other Comp.$31,786
Total$10,885,268

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 5, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
524

PRICE TARGET

Target High$43.00
Target Low$35.00
Target Median$39.00
Target Consensus$39.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$152.61M
NOV
5
THU

PRICE

$36.62 ▼ DOWN 0.35% (−$0.13)
$36.20$36.40$36.60$36.809:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM36.62

About Immunocore Holdings plc

https://www.immunocore.com ↗

Immunocore Holdings plc is a biotech company developing immunotherapies for cancer, infectious, and autoimmune diseases, with products like KIMMTRAK and several clinical-stage programs across oncology and infectious disease areas.

INDUSTRY

Biotechnology

A PRODUCT IMMUNOCORE HOLDINGS PLC IS KNOWN FOR

KIMMTRAK (tebentafusp)
KIMMTRAK (tebentafusp)

KIMMTRAK is the first approved T-cell receptor therapy for unresectable or metastatic uveal melanoma, marking a major breakthrough in immunotherapy and driving most of Immunocore's revenue.

COMPETITORS

COMPETITOR
AURA COMPARE
IDYA COMPARE
IMTX COMPARE
IOVA COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Sale of Therapies$103.69M $104.48M ▲$106.68M ▲$115.93M ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
UNITED STATES$67.3M $69M ▲$67.44M ▼$74.94M ▲
Europe$33.53M $32.05M ▼$34.41M ▲$34.12M ▼
Rest Of World$2.87M $3.42M ▲$4.83M ▲$6.87M ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
24
LISTED HERE
14
RANKED BY POSITION SIZE
IBB
0.11% · 317.0K
SPDW
0.01% · 64.6K
SBIO
0.95% · 62.7K
BBP
1.56% · 50.6K
CANC
0.78% · 44.9K
ONEQ
0.01% · 19.9K
SILX
4.36% · 12.5K
ARWG
2.44% · 10.8K
GERM
3.67% · 9.2K
APIE
0.02% · 5.0K
IBBQ
0.10% · 2.8K
BIB
0.06% · 1.6K
GERD.L
0.00% · 882
TNXT
0.12% · 591

INSTITUTIONAL OWNERSHIP

SHARES OWNED
83.08%
HOLDERS
206
TOP 12 OF 206 · RANKED BY POSITION SIZE
T. Rowe Price Investment Management, Inc.
7.1M sh · $256.63M
Wellington Management Group Llp
5.7M sh · $181.67M
Rtw Investments, LP
4.9M sh · $154.62M
Fmr LLC
4.8M sh · $145.6M
Primecap Management Co/Ca/
4.0M sh · $137.52M
Bellevue Group AG
2.8M sh · $84.32M
Vestal Point Capital, LP
2.8M sh · $83.42M
Tang Capital Management LLC
2.6M sh · $84.12M
Baker Bros. Advisors LP
2.3M sh · $84.38M
Deep Track Capital, LP
2.0M sh · $69.56M
Two Sigma Investments, LP
1.6M sh · $52.36M
Millennium Management LLC
1.6M sh · $50.71M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book2
Overall Score1

INSIDER TRADES

★
DIRECTOR
Ratcliffe Peter John
Purchase · 27.5K shares
2026-05-27
★
DIRECTOR
Peterson Kristine
Purchase · 27.5K shares
2026-05-27
★
DIRECTOR
Pao William
Purchase · 27.5K shares
2026-05-27
★
DIRECTOR
Kaul Siddharth
Purchase · 27.5K shares
2026-05-27

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
NEUTRAL 1
HOLD 1
EQUAL WEIGHT 1
5 GRADES IN THE LAST 12 MONTHS
Mizuho NEUTRAL HC Wainwright & Co. BUY Jefferies HOLD Needham BUY Morgan Stanley EQUAL WEIGHT

SECTORS PEERS

PEERPRICE
ABCL$11.35COMPARE
CLDX$39.12COMPARE
VERA$34.19COMPARE
BHVN$15.41COMPARE
NUVB$6.66COMPARE
HRMY$39.21COMPARE
XERS$8.48COMPARE
MNKD$3.95COMPARE